newsfilter
← Latest News
GlobeNewswire·

Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster

Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccines Agreement reached with global regulators on trial design and da